4.7 Article

Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials

Journal

NANOMATERIALS
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/nano12101735

Keywords

coronaviruses; nanotechnology; engineered nanomaterials; environmental health and safety

Funding

  1. National Science Foundation [2031785]
  2. British Society for Antimicrobial Chemotherapy [BSAC-COVID-81]
  3. Directorate For Engineering
  4. Div Of Chem, Bioeng, Env, & Transp Sys [2031785] Funding Source: National Science Foundation

Ask authors/readers for more resources

This study developed an antimicrobial platform based on engineered water nanostructures (EWNS) using nanotechnology, which effectively inactivated the human coronavirus 229E (a surrogate of SARS-CoV-2) within 30 seconds, demonstrating its potential as a technology against SARS-CoV-2.
The continuing cases of COVID-19 due to emerging strains of the SARS-CoV-2 virus underscore the urgent need to develop effective antiviral technologies. A crucial aspect of reducing transmission of the virus is through environmental disinfection. To this end, a nanotechnology-based antimicrobial platform utilizing engineered water nanostructures (EWNS) was utilized to challenge the human coronavirus 229E (HCoV-229E), a surrogate of SARS-CoV-2, on surfaces. The EWNS were synthesized using electrospray and ionization of aqueous solutions of antimicrobials, had a size in the nanoscale, and contained both antimicrobial agents and reactive oxygen species (ROS). Various EWNS were synthesized using single active ingredients (AI) as well as their combinations. The results of EWNS treatment indicate that EWNS produced with a cocktail of hydrogen peroxide, citric acid, lysozyme, nisin, and triethylene glycol was able to inactivate 3.8 logs of HCoV-229E, in 30 s of treatment. The delivered dose of antimicrobials to the surface was measured to be in pico to nanograms. These results indicate the efficacy of EWNS technology as a nano-carrier for delivering a minuscule dose while inactivating HCoV-229E, making this an attractive technology against SARS-CoV-2.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available